Detrimental Antidepressant Drug–Drug Interactions: Are They Clinically Relevant?

被引:0
|
作者
Sheldon Preskorn
Steve Werder
机构
[1] University of Kansas School of Medicine-Wichita,Department of Psychiatry
来源
Neuropsychopharmacology | 2006年 / 31卷
关键词
antidepressants; drug–drug interactions; cytochrome ; 450 enzymes; serious adverse effects; polypharmacy;
D O I
暂无
中图分类号
学科分类号
摘要
This paper takes the position that detrimental drug–drug interactions (DDIs) involving antidepressants are clinically relevant. In doing so, it begins with a definition of the terms: drug–drug interaction, detrimental, and clinical relevance. It then discusses the issues of proof and provides an overview of the clinically relevant DDIs involving antidepressants. It also gives examples involving drugs besides antidepressants based on the premise that the underlying principles are applicable regardless of the therapeutic classes of the drugs involved.
引用
收藏
页码:1605 / 1612
页数:7
相关论文
共 50 条
  • [21] Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
    Edinoff, Amber N.
    Swinford, Connor R.
    Odisho, Amira S.
    Burroughs, Caroline R.
    Stark, Cain W.
    Raslan, Walid A.
    Cornett, Elyse M.
    Kaye, Adam M.
    Kaye, Alan D.
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (04):
  • [22] Clinically relevant drug interactions of current antifungal agents
    Gubbins, Paul O.
    Heldenbrand, Seth
    MYCOSES, 2010, 53 (02) : 95 - 113
  • [23] Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
    Uwe Christians
    Wolfgang Jacobsen
    Leslie Z. Benet
    Alfonso Lampen
    Clinical Pharmacokinetics, 2002, 41 : 813 - 851
  • [24] Clinically relevant drug interactions; it's time for education
    Verbeek, R.
    Richir, M.
    Tichelaar, J.
    van Agtmael, M.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S45 - S45
  • [25] Mechanisms of clinically relevant drug interactions associated with tacrolimus
    Christians, U
    Jacobsen, W
    Benet, LZ
    Lampen, A
    CLINICAL PHARMACOKINETICS, 2002, 41 (11) : 813 - 851
  • [26] DALCETRAPIB HAS NO CLINICALLY RELEVANT DRUG-DRUG INTERACTIONS WITH PRAVASTATIN OR ROSUVASTATIN
    Derks, M.
    Abt, M.
    Phelan, M.
    Turnbull, L.
    Meneses-Lorente, G.
    Bech, N.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [27] Clinically relevant drug-drug interactions among elderly people with dementia
    Sonnerstam, Eva
    Sjolander, Maria
    Lovheim, Hugo
    Gustafsson, Maria
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (10) : 1351 - 1360
  • [28] Renal Transporter-Mediated Drug-Drug Interactions: Are They Clinically Relevant?
    Lepist, Eve-Irene
    Ray, Adrian S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 : S73 - S81
  • [29] IMPACT OF THE DRUG-DRUG INTERACTION DATABASE SFINX ON THE PREVALENCE OF CLINICALLY RELEVANT DRUG INTERACTIONS
    Andersson, M. L.
    Eiermann, B.
    Wettermark, B.
    Bottiger, Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 138 - 138
  • [30] Antidepressant-drug interactions are potentially but rarely clinically significant
    DeVane, C. Lindsay
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 (08) : 1594 - 1604